Logos Global Management LP — 13F Holdings & Portfolio
CIK 1792126 · latest 13F-HR filed 2026-08-14
Logos Global Management LP manages $2.32B in 13F-reported U.S. long-equity assets across 68 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ERAS (9.58%), ABVX (5.87%), RVMD (5.64%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 25 new positions, exited 20, added to 23, and trimmed 17.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
BLDG C, SUITE C3-350
SAN FRANCISCO, CA 94129
$2.32B
Long-equity book
68
Distinct positions
2026-06-30
Filed 2026-08-14
+25 / −20 / ↑23 / ↓17
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- CELLDEX THERAPEUTICS INC NEW$63.9M +447.4%
- ABIVAX SA$61.3M +81.6%
- DIANTHUS THERAPEUTICS INC$44.4M +132.3%
- ERASCA INC$42.2M +23.4%
- CG ONCOLOGY INC$32.1M +82.6%
Top Trims
- REVOLUTION MEDICINES INC-$63.4M -32.6%
- IMMUNOCORE HLDGS PLC-$26.2M -57.9%
- RHYTHM PHARMACEUTICALS INC-$25.3M -64.5%
- ACADIA PHARMACEUTICALS INC-$10.4M -62.1%
- OLEMA PHARMACEUTICALS INC-$7.7M -16.1%
New Positions
- BIONTECH SE$94.4M
- VERA THERAPEUTICS INC$94.4M
- BELITE BIO INC$38.5M
- ACHIEVE LIFE SCIENCE INC$35.4M
- COGENT BIOSCIENCES INC$34.8M
Exited Positions
- CENTESSA PHARMACEUTICALS PLC$84.4M
- TERNS PHARMACEUTICALS INC$79.1M
- CYTOKINETICS INC$57.7M
- UNITED THERAPEUTICS CORP DEL$47.4M
- MADRIGAL PHARMACEUTICALS INC$44.5M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ERASCA INC | ERAS | 29479A108 | $222.6M | 9.58% | 12,150,000 | SH |
| 2 | ABIVAX SA | ABVX | 00370M103 | $136.5M | 5.87% | 1,024,000 | SH |
| 3 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $131.1M | 5.64% | 700,000 | SH |
| 4 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $111.8M | 4.81% | 3,000,000 | SH |
| 5 | BIONTECH SE | BNTX | 09075V102 | $94.4M | 4.07% | 1,015,000 | SH |
| 6 | VERA THERAPEUTICS INC | VERA | 92337R101 | $94.4M | 4.06% | 2,200,000 | SH |
| 7 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $89.1M | 3.84% | 2,850,000 | SH |
| 8 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $87.0M | 3.75% | 260,000 | SH |
| 9 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $78.1M | 3.36% | 2,100,000 | SH |
| 10 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $78.0M | 3.36% | 800,000 | SH |
| 11 | CG ONCOLOGY INC | CGON | 156944100 | $71.0M | 3.06% | 1,000,000 | SH |
| 12 | DISC MEDICINE INC | IRON | 254604101 | $64.0M | 2.76% | 875,000 | SH |
| 13 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $57.7M | 2.49% | 1,935,000 | SH |
| 14 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $56.6M | 2.44% | 2,550,000 | SH |
| 15 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $52.1M | 2.24% | 2,675,000 | SH |
| 16 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $52.0M | 2.24% | 5,300,000 | SH |
| 17 | DESIGN THERAPEUTICS INC | DSGN | 25056L103 | $43.4M | 1.87% | 3,000,000 | SH |
| 18 | OLEMA PHARMACEUTICALS INC | OLMA | 68062P106 | $40.1M | 1.73% | 3,208,875 | SH |
| 19 | BELITE BIO INC | BLTE | 07782B104 | $38.5M | 1.66% | 250,000 | SH |
| 20 | ACHIEVE LIFE SCIENCE INC | ACHV | 004468500 | $35.4M | 1.53% | 5,425,000 | SH |
| 21 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $35.1M | 1.51% | 1,880,000 | SH |
| 22 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $34.8M | 1.50% | 900,000 | SH |
| 23 | ARRIVENT BIOPHARMA INC | AVBP | 04272N102 | $34.7M | 1.50% | 1,000,000 | SH |
| 24 | CRESCENT BIOPHARMA INC. | CBIO | G2545C104 | $34.2M | 1.47% | 1,900,000 | SH |
| 25 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $31.8M | 1.37% | 2,250,000 | SH |
| 26 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $28.3M | 1.22% | 1,050,000 | SH |
| 27 | REPLIMUNE GROUP INC | REPL | 76029N106 | $27.7M | 1.19% | 2,500,000 | SH |
| 28 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $27.2M | 1.17% | 450,000 | SH |
| 29 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $26.8M | 1.16% | 500,000 | SH |
| 30 | IMMUNOVANT INC | IMVT | 45258J102 | $25.6M | 1.10% | 665,000 | SH |
| 31 | JADE BIOSCIENCES INC | JBIO | 008064206 | $25.0M | 1.08% | 1,125,000 | SH |
| 32 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $23.6M | 1.02% | 465,000 | SH |
| 33 | VERADERMICS INC | MANE | 922967104 | $22.1M | 0.95% | 180,000 | SH |
| 34 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $21.3M | 0.91% | 1,150,000 | SH |
| 35 | ARCUS BIOSCIENCES INC | RCUS | 03969F109 | $20.0M | 0.86% | 650,000 | SH |
| 36 | SUMMIT THERAPEUTICS INC | SMMT | 86627T108 | $19.7M | 0.85% | 1,350,000 | SH |
| 37 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $19.1M | 0.82% | 600,000 | SH |
| 38 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $19.0M | 0.82% | 585,000 | SH |
| 39 | MINERVA NEUROSCIENCES INC | NERV | 603380205 | $18.3M | 0.79% | 3,288,777 | SH |
| 40 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $18.1M | 0.78% | 722,020 | SH |
| 41 | CRISPR THERAPEUTICS AG | CRSP | H17182108 | $16.4M | 0.70% | 300,000 | SH |
| 42 | DBV TECHNOLOGIES S A | DBVT | 23306J309 | $15.0M | 0.65% | 915,000 | SH |
| 43 | PARABILIS MEDICINES INC | PBLS | 698955101 | $14.4M | 0.62% | 525,000 | SH |
| 44 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $13.9M | 0.60% | 125,000 | SH |
| 45 | VOR BIOPHARMA INC | VOR | 929033207 | $12.0M | 0.52% | 650,000 | SH |
| 46 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $11.0M | 0.47% | 200,000 | SH |
| 47 | IMMIX BIOPHARMA INC | IMMX | 45258H106 | $10.3M | 0.44% | 1,000,000 | SH |
| 48 | Q32 BIO INC | QTTB | 746964105 | $10.2M | 0.44% | 800,000 | SH |
| 49 | ODYSSEY THERAPEUTICS INC | ODTX | 67613T104 | $9.8M | 0.42% | 521,736 | SH |
| 50 | ANNEXON INC | ANNX | 03589W102 | $8.6M | 0.37% | 1,500,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $2.32B | 68 | 0001172661-26-003529 |
| 2026-03-31 | 2026-05-15 | $2.00B | 66 | 0001172661-26-002196 |
| 2025-12-31 | 2026-02-17 | $1.65B | 69 | 0001172661-26-001209 |
| 2025-09-30 | 2025-11-14 | $1.12B | 59 | 0001172661-25-004983 |